Royalty Pharma plc Class A

Stage 2 · Advancing · week 49

As of Oct 22, 2026, Royalty Pharma is in Stage 2, the uptrend phase, now in week 49 (since Nov 6, 2025). It closed at $63.75, at its 52-week high and above its 200-day average, which is rising.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. More about the company

$63.75

+2.57% today

$36.8B · Large cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is RPRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 37w

S2 50w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 12w → S2 7w → S3 5w → S4 9w → S1 10w → S2 1w → S1 1w → S4 10w → S1 1w → S2 37w → S3 2w → S2 50w current

Total tracked: 165 weeks across 13 stage runs.

RPRX among Biotechnology66th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…66	RPRXRoyalty Pharma plc Class A	Stage 2 · wk 49	92	+10.6%

vs 52W High

-0.3%

$35.72 lo$63.96 hi

Near 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 49

1w13w26w

Week 49, mature

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

22.1%

200 DMA: $52.20 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.93x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+10.6%

+8.8%

+29.5%

YTD

+66.3%

+73.4%

Scan Membership

Breakout Watch

Latest: 2025-01-30

6 appearances in last 60 days. First seen: 2022-01-13.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 49 · Vol 0.93x

2026-10-21S2

Wk 48 · Vol 0.91x

2026-10-20S2

Wk 48 · Vol 0.82x

2026-10-19S2

Wk 48 · Vol 0.92x

2026-10-16S2

Wk 48 · Vol 1.93x

2026-10-15S2

Wk 48 · Vol 1.13x

2026-10-14S2

Wk 47 · Vol 0.94x

2026-10-13S2

Wk 47 · Vol 1.19x

2026-10-12S2

Wk 47 · Vol 0.82x

2026-10-09S2

Wk 47 · Vol 0.96x

2026-10-08S2

Wk 47 · Vol 0.95x

2026-10-07S2

Wk 46 · Vol 1.23x

Moving averages & range

50 DMA

$59.61

200 DMA

$52.20

52W High

$63.96

52W Low

$35.72

5D Low

$60.27

Resistance levels (recent highs)

20d High

$63.75

60d High

$63.96

120d High

$63.96

250d High

$63.96

Next resistance

+0.3%

to 60d High

P/E (TTM)

33.9

Forward 11.0

Earnings Growth (YoY)

-46.3%

Revenue +16.5%

ROE

+14.0%

Profit margin +32.0%

Dividend Yield

1.51%

P/B 4.2

Royalty Pharma: quick answers

What stage is Royalty Pharma in?

As of Oct 22, 2026, Royalty Pharma (RPRX) is in Stage 2, the uptrend phase. It entered Stage 2 on Nov 6, 2025 and is in week 49. What the four stages mean

Is Royalty Pharma in an uptrend?

Yes. Royalty Pharma is in a Stage 2 uptrend. It trades 22.1% above its 200-day average, which is rising.

How far is Royalty Pharma from its 52-week high?

Royalty Pharma closed at $63.75 on Oct 22, 2026, at its 52-week high. Its 52-week low is $35.72.

How has Royalty Pharma performed over the past year?

As of Oct 22, 2026, Royalty Pharma is up 73.4% over the past year and up 66.3% so far in 2026.

Which sector and industry is Royalty Pharma in?

Royalty Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.